STORM Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities

<p><a href="https://open-patsnap-com.libproxy1.nus.edu.sg/marketplace/mcp-servers?from=Synapse_SEO_blog3" target="_blank" rel="noopener"><img src="https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/image_92706a9ee1.png" alt="PatSnap MCP servers used for the STORM Therapeutics BD opportunity scan"></a></p><p><strong>This STORM Therapeutics Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows.</strong> Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP tests for recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. <a href="https://open-patsnap-com.libproxy1.nus.edu.sg/marketplace/mcp-servers?from=Synapse_SEO_blog3" target="_blank" rel="noopener">Explore the MCP servers used in this report.</a></p><p><em>Decision date: 22 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply a usable record and must not be read as evidence of absence.</em></p><h2>Executive BD thesis</h2><p>STORM Therapeutics is screened as a potential partnering counterparty across asset licensing, regional commercialization, co-development, platform access and evidence-generation structures. The organization pipeline call returned 10 records at the decision date. The lead returned asset is <strong>STC-15</strong>, associated with METTL3 and Advanced cancer, Dedifferentiated Liposarcoma, Leiomyosarcoma, Solid tumor, at Phase 2. The immediate objective is to identify a narrow, executable right set and the evidence package required to test strategic fit.</p><p>A high-quality first meeting should confirm the current development owner, decision rights, territory availability, stage definitions, program status, patent ownership, third-party licenses, CMC readiness, clinical evidence, regulatory history and management’s preferred transaction structure. Pipeline size is a starting signal, not a substitute for strategic fit or diligence.</p><h2>Partnering shortlist</h2><table><thead><tr><th>Priority</th><th>Asset / workstream</th><th>Owner</th><th>Stage</th><th>Evidence package</th><th>IP risk screen</th><th>Deal precedent</th><th>Outreach rationale</th></tr></thead><tbody><tr><td>1</td><td><strong>STC-15</strong></td><td>STORM Therapeutics Ltd.</td><td>Phase 2</td><td>Pipeline record: METTL3; Advanced cancer, Dedifferentiated Liposarcoma, Leiomyosarcoma, Solid tumor. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index.</td><td>Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate.</td><td>Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes</td><td>Phase 2 asset with METTL3 exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures.</td></tr><tr><td>2</td><td><strong>STM-2457</strong></td><td>STORM Therapeutics Ltd.</td><td>Preclinical</td><td>Pipeline record: METTL3; Coronavirus Infections. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index.</td><td>Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate.</td><td>Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes</td><td>Preclinical asset with METTL3 exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures.</td></tr><tr><td>3</td><td><strong>STM-9005</strong></td><td>STORM Therapeutics Ltd.</td><td>Preclinical</td><td>Pipeline record: METTL1; Acute Myeloid Leukemia, Advanced cancer, Melanoma, Pancreatic Ductal Adenocarcinoma. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index.</td><td>Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate.</td><td>Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes</td><td>Preclinical asset with METTL1 exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures.</td></tr><tr><td>4</td><td><strong>STM11315</strong></td><td>STORM Therapeutics Ltd.</td><td>Preclinical</td><td>Pipeline record: DHX9; Neoplasms. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index.</td><td>Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate.</td><td>Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes</td><td>Preclinical asset with DHX9 exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures.</td></tr><tr><td>5</td><td><strong>STM3675</strong></td><td>STORM Therapeutics Ltd.</td><td>Preclinical</td><td>Pipeline record: METTL3; Acute Megakaryoblastic Leukemia. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index.</td><td>Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate.</td><td>Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes</td><td>Preclinical asset with METTL3 exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures.</td></tr></tbody></table><p><strong>Shortlist interpretation.</strong> Priority one should receive the fastest outreach only after the returned owner and stage are reconfirmed. Lower-ranked rows preserve option value and may support a regional license, co-development collaboration, asset carve-out, structured option, research partnership or financing-linked agreement. Any mismatch among asset name, owner, indication and stage is itself a diligence signal that may reflect a transfer, dormant program, territory split or portfolio reprioritization.</p><p><a href="https://open-patsnap-com.libproxy1.nus.edu.sg/marketplace/mcp-servers?from=Synapse_SEO_blog3" target="_blank" rel="noopener"><img src="https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/image_2ed6f2cf76.png" alt="PatSnap Life Sciences MCP workflow for STORM Therapeutics"></a></p><h2>Pipeline and evidence-package readout</h2><p>The organization pipeline fetch anchors asset identity, target, indication and development stage when those fields are returned. Reconcile them against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, subgroup results, safety narratives, manufacturing comparability, stability data, health-authority feedback and the sponsor’s integrated development plan.</p><p>Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across the company record, trial registries and regulatory sources. A stage label should be translated into a milestone map with dates, endpoints, decision gates and remaining cost. Where the MCP result is missing or ambiguous, do not fill the gap by assumption: make the refresh and reconciliation an explicit condition before valuation.</p><h2>Deal precedents and structure signals</h2><table><thead><tr><th>Date</th><th>Transaction</th><th>Status</th><th>Disclosed economics</th></tr></thead><tbody><tr><td>2021-10-14</td><td>Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes</td><td>Active</td><td>Not disclosed</td></tr></tbody></table><p>Transaction precedents guide structure rather than mechanically determine price. Normalize every comparison for stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones, sublicensing, governance, termination and change-of-control provisions. Undisclosed economics can still reveal counterparties, strategic intent and preferred transaction form. A missing search result should trigger a broader licensor/licensee and asset-level search before negotiation.</p><h2>Financial capacity and partnering pressure</h2><ul><li><strong>Stoke Therapeutics, Inc. - 2023 Annual report</strong>: Stoke Therapeutics, Inc. - 2023 Annual report Governance As of December 31, 2023 and 2022 we had $201.4 million and $229.6 million, respectively, in cash, cash equivalents and marketable securities. Since inception, we have had operating losses, the majority of which are attributable to research and development activities. Our net losses were $104.7 million and $101.1 million for the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, we had an accumulated deficit of $401.8 million and as of December 31, 2022, we had an accumulated deficit of $297.2 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change i</li><li><strong>TOMI Environmental Solutions, Inc. - 2022 Quarterly report</strong>: TOMI Environmental Solutions, Inc. - 2022 Quarterly report Research and Development Cash provided by financing activities for nine months ended September 30 2022 and 2021 was $25,000 and $4,582,000, respectively. The decrease as a result of the proceeds we received in connection with the sale of our common stock and warrants in the prior year period. Liquidity Our revenues can fluctuate due to the following factors, among others: · ramp up and expansion of our internal sales force and manufacturers’ representatives; l h f l l · length of our sales cycle; · length of installation of our CES; · global response to the outbreak of COVID-19 Pandemic and or new Pandemics or diseases of concern; · customer budget cycles and allocations; · expansion into new territories and markets; and · timing of orders from distributors. We could incur operating losses and an increase of costs related to the </li><li><strong>RHYTHM PHARMACEUTICALS, INC. - 2024 Annual report</strong>: RHYTHM PHARMACEUTICALS, INC. - 2024 Annual report Comparison of years ended December 31, 2024 and 2023 Research and development expense. Research and development expense increased by $103.0 million to $238.0 million in 2024 from $135.0 million in 2023, an increase of 76%. The increase was primarily due to the following: acquired in-process research and development costs associated with the acquisition of LGC’s proprietary compound bivamelagon of $92.4 million;fi an increase of $8.1 million in salaries, benefits and stock-based compensation related to the hiring of additional full-time employees in order to support the growth of our research and development programs; an increase of $7.5 million in our Phase 3 acquired hypothalamic obesity trial, our Phase 1 clinical trial of RM-718 and the Phase 2 bivamelagon trial acquired from LGC. These costs were partially offset by reduced activity d</li></ul><p>Translate financial signals into BD questions. Confirm unrestricted cash, quarterly operating use, committed trials, debt and royalty financing, covenant constraints, near-term milestone receipts, commercial investment and management’s minimum runway threshold. A well-capitalized company may prefer a premium strategic collaboration; a constrained company may prioritize non-dilutive funding, regional monetization, cost sharing or a staged option.</p><h2>Current-awareness events and outreach triggers</h2><p>The Current Awareness <code>news_search</code> call did not return a parseable recent-event record at the decision date. Refresh the search before outreach and reconcile press releases, trial updates, regulatory events, financing announcements, management changes and partnering disclosures. Do not interpret the missing return as absence of news.</p><p>The best outreach window often follows a data readout, regulatory interaction, financing, portfolio review, leadership change or new transaction. Build a trigger calendar and identify the person who owns the asset, the therapeutic-area BD lead, the regional commercial lead and alliance-management stakeholders. Outreach should cite one verified event and one specific contribution the prospective partner can make.</p><h2>IP and freedom-to-operate risk screen</h2><p>The IP review is a gating workstream, not a footnote. Request the full patent-family schedule, inventorship and assignment history, prosecution status, expected expiries, patent-term adjustment or extension assumptions, opposition and litigation history, third-party licenses, field and territory restrictions, royalties, reach-through clauses, government rights and material-transfer obligations. Map composition-of-matter, method-of-use, formulation, manufacturing, biomarker, combination, platform and delivery claims to the exact rights proposed in the deal.</p><p>Screen risk as medium by default when an asset and owner are returned but the patent package has not been reviewed; elevate it to high where ownership, stage or program status is not returned. A license must match patents, know-how, data, regulatory references, materials, manufacturing rights and sublicensing rights to the precise field and geography. Complete a claim-level patent and FTO review before exclusivity, valuation or term-sheet approval.</p><h2>Recommended deal structures</h2><ul><li><strong>Regional license:</strong> useful when development or commercial capabilities differ by territory; define data access, regulatory responsibilities, supply, transfer pricing and reversion rights.</li><li><strong>Co-development:</strong> appropriate when both parties contribute clinical, biomarker, regulatory or commercial capabilities; specify cost sharing, governance, global strategy and opt-out economics.</li><li><strong>Option-to-license:</strong> reduces uncertainty before a defined data event; specify option fee, exercise trigger, diligence standard, exclusivity period and pre-agreed economics.</li><li><strong>Research or platform collaboration:</strong> suitable when the value resides in discovery or delivery capability; define targets, ownership of foreground IP, publication, replacement rights and downstream options.</li><li><strong>Structured financing:</strong> may combine equity, milestone funding, royalties or territory monetization; test covenant, accounting, control and change-of-control implications.</li></ul><h2>Outreach rationale and first-contact plan</h2><ol><li><strong>Identify the decision owner.</strong> Map the asset team, corporate-development lead, therapeutic-area leadership, regional commercial lead and alliance-management stakeholders.</li><li><strong>Lead with one verifiable gap.</strong> Focus on territory, evidence, diagnostics, manufacturing, delivery, financing or combination strategy rather than a generic partnership request.</li><li><strong>Attach a concise evidence package.</strong> Include the returned stage, indication footprint, relevant transaction precedent, partner contribution, proposed work plan and decision gates.</li><li><strong>Offer a structure.</strong> Present one primary and one fallback structure with clear rights, funding, governance and diligence assumptions.</li><li><strong>Define the diligence sequence.</strong> Request data-room access, IP/FTO materials, CMC documents, safety data, regulatory correspondence, economics and encumbrances before exclusivity.</li></ol><h2>Decision memo</h2><p><strong>ADVANCE TARGETED OUTREACH, SUBJECT TO EVIDENCE REFRESH.</strong> STORM Therapeutics offers a credible screening case because the MCP workflow identifies either a returned pipeline opportunity or a concrete set of evidence gaps that can be tested rapidly. The first contact should be tailored to a named asset where available, quantify the partner’s contribution, acknowledge IP and execution risks and avoid using pipeline count as a proxy for value.</p><p><strong>Required next diligence:</strong> refresh all four MCP searches; fetch full deal records for economics and rights; reconcile the newest financial filing and public event disclosures; verify owner and license chain; obtain patent-family and FTO work; review CMC, safety and regulatory materials; and model risk-adjusted economics by indication, territory and transaction structure.</p><p><a href="https://open-patsnap-com.libproxy1.nus.edu.sg/marketplace/mcp-servers?from=Synapse_SEO_blog3" target="_blank" rel="noopener"><img src="https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/image_dddd7a2c83.png" alt="Explore PatSnap MCP servers for STORM Therapeutics partnering intelligence"></a></p><p><a href="https://open-patsnap-com.libproxy1.nus.edu.sg/marketplace/mcp-servers?from=Synapse_SEO_blog3" target="_blank" rel="noopener"><strong>Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.</strong></a></p><hr><p><strong>Data provenance:</strong> PatSnap Company & Deal Intelligence MCP (<code>organization_pipeline_fetch</code>, <code>drug_deal_search</code>, <code>financial_report_search</code>) and Current Awareness MCP (<code>news_search</code>); accessed 22 July 2026. Counts, ownership and statuses may change as records update.</p>